Biohaven (BHVN) Non-Current Assets (2021 - 2026)
Biohaven (BHVN) posted Non-Current Assets of $80.8 million for Q1 2026, down 2.84% sequentially from $83.1 million in Q4 2025, and up 6.0% YoY from $76.2 million in Q1 2025.
Analysis
Biohaven (BHVN) Non-Current Assets (2021 - 2026) Analysis & Trends
Biohaven has reported Non-Current Assets for 6 years, with the latest figure at $80.8 million in Q1 2026.
- Quarterly Non-Current Assets rose 6.0% year-over-year to $80.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $325.0 million (up 10.45% YoY) and the FY2025 annual result came in at $83.1 million, up 8.46% from the prior year.
- Non-Current Assets retreated to $80.8 million in Q1 2026 per BHVN's latest filing, from $83.1 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $85.5 million in Q3 2025 and troughed at $55.1 million in Q3 2022.
- A 5-year average of $73.9 million and a median of $74.0 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2024: Non-Current Assets surged 58.38% in 2022, then declined 5.75% in 2024.
- Over 5 years, Non-Current Assets stood at $74.8 million in 2022, then fell by 5.41% to $70.8 million in 2023, then rose by 8.29% to $76.6 million in 2024, then advanced by 8.46% to $83.1 million in 2025, then fell by 2.84% to $80.8 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $80.8 million, $83.1 million, and $85.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Biohaven | 2.37 Bn | 2.10 Bn | - | 74.18 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 74.18 Mn |
| Mar 31, 2026 | 80.76 Mn |
| Dec 31, 2025 | 83.12 Mn |
| Sep 30, 2025 | 85.51 Mn |
| Jun 30, 2025 | 75.59 Mn |
| Mar 31, 2025 | 76.19 Mn |
| Dec 31, 2024 | 76.64 Mn |
| Sep 30, 2024 | 70.02 Mn |
| Jun 30, 2024 | 71.37 Mn |
| Mar 31, 2024 | 69.79 Mn |
| Dec 31, 2023 | 70.77 Mn |
| Sep 30, 2023 | 72.17 Mn |
| Jun 30, 2023 | 72.62 Mn |
| Mar 31, 2023 | 74.05 Mn |
| Dec 31, 2022 | 74.82 Mn |
| Sep 30, 2022 | 55.10 Mn |
| Dec 31, 2021 | 47.24 Mn |